PTEN Antibody, Novus Biologicals™

Catalog No.	Quantity
NBP24453802	0.2 mg

Catalog No. NBP24453802 Supplier Novus Biologicals Supplier No. NBP2445380.2MG

Description

Rabbit Polyclonal Antibody

Specifically detects PTEN in Human, Mouse samples, and it is validated for Flow Cytometry, Immunofluorescence, Western Blotting

PTEN Polyclonal antibody specifically detects PTEN in Human, Mouse samples. It is validated for Western Blot, Flow Cytometry, Immunohistochemistry-Paraffin, Immunofluorescence.

Specifications

• Antigen: PTEN
• Applications: Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence
• Classification: Polyclonal
• Concentration: 0.2mg/mL
• Conjugate: Unconjugated
• Dilution: Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1:10-1:500, Immunofluorescence 1 - 2 ug/ml
• Formulation: 10mM PBS and 0.05% BSA with 0.05% Sodium Azide
• Gene Accession No.: P60484
• Gene Alias: BZS, EC 3.1.3.16,10q23del, EC 3.1.3.48, EC 3.1.3.67, GLM2, MMAC1 phosphatase and tensin homolog deleted on chromosome 10, MMAC1MGC11227, Mutated in multiple advanced cancers 1, phosphatase and tensin homologDEC, phosphatidylinositol-34,5-trisphosphate 3-phosphatase and dual-specificityprotein phosphatase PTEN, PTEN1, TEP1MHAM
• Gene Symbols: PTEN
• Host Species: Rabbit
• Immunogen: Recombinant full-length human PTEN protein
• Molecular Weight of Antigen: 55 kDa
• Purification Method: Protein A purified
• Quantity: 0.2 mg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 5728
• Test Specificity: Recognizes a protein of 55kDa, which is identified as PTEN. PTEN is one of the most commonly lost tumor suppressors in human cancer; in fact, up to 70% of men with prostate cancer are estimated to have lost a copy of the PTEN gene at the time of diagnosis. During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, and prostate cancer; and reduced expression is found in many other tumor types such as lung and breast cancer. In breast and prostate cancer, loss of PTEN expression has been shown to correlate positively with advanced stage. Furthermore, PTEN mutation also causes a variety of inherited predispositions to cancer.
• Target Species: Human, Mouse
• Content And Storage: Store at 4C.
• Form: Purified
• Isotype: IgG

For Research Use Only